Prime Capital Investment Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $59.9M | Sell |
65,157
-5,565
| -8% | -$5.64M | 0.69% | 37 |
|
|
2025
Q4 | $76M | Buy |
70,722
+1,744
| +3% | +$1.67M | 0.93% | 25 |
|
|
2025
Q3 | $52.6M | Buy |
68,978
+4,774
| +7% | +$3.55M | 0.66% | 40 |
|
|
2025
Q2 | $50M | Sell |
64,204
-18,803
| -23% | -$14.6M | 0.66% | 39 |
|
|
2025
Q1 | $68.6M | Buy |
83,007
+22,114
| +36% | +$18.4M | 0.8% | 29 |
|
|
2024
Q4 | $47M | Sell |
60,893
-3,479
| -5% | -$2.88M | 0.68% | 38 |
|
|
2024
Q3 | $57M | Buy |
64,372
+1,635
| +3% | +$1.47M | 0.81% | 33 |
|
|
2024
Q2 | $56.8M | Sell |
62,737
-8,097
| -11% | -$6.48M | 0.84% | 29 |
|
|
2024
Q1 | $55.1M | Sell |
70,834
-7,211
| -9% | -$5.13M | 0.77% | 29 |
|
|
2023
Q4 | $45.5M | Buy |
78,045
+8,956
| +13% | +$5.23M | 0.69% | 32 |
|
|
2023
Q3 | $37.1M | Buy |
69,089
+8,857
| +15% | +$4.56M | 0.76% | 26 |
|
|
2023
Q2 | $28.2M | Buy |
60,232
+30,463
| +102% | +$12.8M | 0.56% | 43 |
|
|
2023
Q1 | $10.2M | Sell |
29,769
-19,234
| -39% | -$6.49M | 0.42% | 53 |
|
|
2022
Q4 | $17.9M | Buy |
49,003
+27,713
| +130% | +$9.83M | 0.68% | 38 |
|
|
2022
Q3 | $6.88M | Buy |
21,290
+7,653
| +56% | +$2.42M | 0.4% | 50 |
|
|
2022
Q2 | $4.42M | Sell |
13,637
-4,297
| -24% | -$1.29M | 0.26% | 70 |
|
|
2022
Q1 | $4.95M | Sell |
17,934
-209
| -1% | -$53.8K | 0.28% | 73 |
|
|
2021
Q4 | $5.01M | Buy |
18,143
+8,733
| +93% | +$2.21M | 0.27% | 74 |
|
|
2021
Q3 | $2.17M | Sell |
9,410
-15,369
| -62% | -$3.79M | 0.14% | 127 |
|
|
2021
Q2 | $5.69M | Buy |
24,779
+1,988
| +9% | +$399K | 0.33% | 60 |
|
|
2021
Q1 | $4.26M | Buy |
22,791
+12,301
| +117% | +$2.41M | 0.31% | 64 |
|
|
2020
Q4 | $1.77M | Buy |
+10,490
| New | +$1.57M | 0.14% | 126 |
|
|
2020
Q3 | – | Sell |
-797
| Closed | -$131K | – | 478 |
|
|
2020
Q2 | $131K | Sell |
797
-224
| -22% | -$34.4K | 0.01% | 258 |
|
|
2020
Q1 | $142K | Sell |
1,021
-229
| -18% | -$31.5K | 0.02% | 216 |
|
|
2019
Q4 | $164K | Sell |
1,250
-8
| -0.6% | -$927 | 0.02% | 206 |
|
|
2019
Q3 | $141K | Buy |
+1,258
| New | +$140K | 0.02% | 221 |
|
|
2019
Q1 | – | Sell |
-538
| Closed | -$62K | – | 394 |
|
|
2018
Q4 | $62K | Buy |
538
+438
| +438% | +$48.9K | 0.02% | 147 |
|
|
2018
Q3 | $11K | Sell |
100
-200
| -67% | -$20K | ﹤0.01% | 237 |
|
|
2018
Q2 | $26K | Hold |
300
| – | – | 0.01% | 225 |
|
|
2018
Q1 | $23K | Buy |
+300
| New | +$24.2K | 0.02% | 184 |
|
Other funds holding LLY
VCM
VPM
Prime Capital Investment Advisors's LLY Position: Q1 2026 in Review
Prime Capital Investment Advisors reduced its Eli Lilly (LLY) stake by 7.9% in Q1 2026, selling an estimated $5.64M and leaving 65,157 shares worth $59.9M. The position accounts for 0.69% of the portfolio, ranked #37.
Prime Capital Investment Advisors first reported a position in LLY in Q1 2018 and has held it in 30 quarters since. The position peaked at $76M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Prime Capital Investment Advisors held 65,157 shares of Eli Lilly worth $59.9M as of Q1 2026.
- Prime Capital Investment Advisors sold 5,565 Eli Lilly shares in Q1 2026, an estimated $5.64M.
- Eli Lilly made up 0.69% of Prime Capital Investment Advisors's portfolio in Q1 2026, its #37 holding.
- Prime Capital Investment Advisors first reported a position in Eli Lilly in Q1 2018 and has held it in 30 quarters since.
- Prime Capital Investment Advisors's Eli Lilly position peaked at $76M in Q4 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Prime Capital Investment Advisors's 13F filing for Q1 2026, filed 8 May 2026.